ANP Peptide Receptor Signalling: NPR-A, Guanylyl Cyclase and the cGMP Branch

The natriuretic peptide receptor family in the mammalian literature has three members that matter here. NPR-A, also written GC-A or NPR1, is the guanylyl cyclase-linked receptor that ANP activates most potently. NPR-B, or GC-B, preferentially responds to CNP. NPR-C carries no cyclase domain and is described in most papers as a clearance receptor, although signalling roles for it have also been reported.

Two of the three generate cGMP and one does not. That single structural fact explains a large share of the contradictory results in my files. A preparation rich in NPR-C removes peptide from the medium without producing a second messenger signal, so a binding readout and a functional readout can disagree for reasons that have nothing at all to do with the ligand itself. I keep anp peptide receptor npr-a signalling separate from ligand-level questions for exactly this reason.

NPR-A is a single-pass membrane protein. The extracellular region binds ligand, one transmembrane helix crosses the bilayer, and the intracellular portion carries a kinase-homology domain followed by the cyclase catalytic domain. The kinase-homology region does not act as a protein kinase in the ordinary sense; it is described as a regulatory module that sets the receptor response to ATP and to phosphorylation state.

The receptor is understood to work as a dimer or multimeric assembly. Ligand binding on the outside is coupled to a change in the intracellular cyclase domains that raises the rate at which GTP is converted to cGMP. Exactly how that conformational change crosses one transmembrane helix per subunit is still an open question in the structural literature, and I have marked it as unresolved in my notes rather than as settled. Reviews of anp peptide receptor npr-a signalling usually stop at this level of detail, which is where my questions start.

Once cyclase activity rises, cGMP accumulates in the cell. The branch usually described in the physiology literature runs through cGMP-dependent protein kinase, written PKG, and through cGMP-gated channels and phosphodiesterases. Which of these dominates depends entirely on the cell type, and a vascular smooth muscle preparation and a renal tubular line do not hand back the same answer, so I have stopped expecting them to.

The phosphodiesterases are the reason a cGMP signal is transient. PDE activity shapes the response in time at least as much as receptor activation shapes its size. Reading anp peptide receptor npr-a signalling without naming the PDE background is, in my experience, the fastest way to reach a conclusion the data does not support.

Receptor responses in cell models are not stable over long exposures. The literature describes desensitisation of the cyclase response after sustained stimulation, internalisation of ligand-receptor complexes, and down-regulation of receptor number measured as reduced binding capacity. These are three different measurements and I try not to regard them as synonyms, because a paper may report one and imply another.

Phosphorylation of the kinase-homology region and dephosphorylation of the receptor are both invoked as mechanisms, and the balance between them appears to differ between cell systems. My own reading of anp peptide receptor npr-a signalling is that the desensitisation literature is the least standardised part of the record: exposure windows, media and readouts vary so much that cross-paper comparison is fragile.

Selectivity in this family is a ratio, not a property. ANP activates NPR-A potently and binds NPR-C as well, so any statement about selectivity has to say which two receptors are being compared and in what format. A binding affinity ratio and a functional potency ratio can differ substantially, and I have seen both quoted as though they were the same number.

This is where my notes on anp peptide receptor npr-a signalling most often disagree with summaries I find elsewhere. A peptide that looks highly selective in a binding assay may look less selective in a cGMP accumulation assay, because the clearance receptor contributes to one readout and subtracts from the other.

Three formats dominate the record. Radioligand binding measures affinity and receptor abundance directly, usually with iodinated peptide and a separation step. cGMP accumulation measures the functional consequence of cyclase activation, and it is the format most papers rely on. Second messenger and reporter readouts sit downstream again and add another layer between receptor and number.

Each format answers a different question, and the honest reading of anp peptide receptor npr-a signalling keeps them apart. Binding tells you a ligand occupies a site; it says nothing about whether that site catalyses anything. cGMP accumulation tells you catalysis happened; on its own it does not tell you which receptor did it, which is why receptor-negative or receptor-blocked conditions appear in the better papers. Fuller context sits on my core page on anp peptide.